{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:08:36Z","timestamp":1790633316801,"version":"4.1.0"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T00:00:00Z","timestamp":1547683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0210476","type":"journal-article","created":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T18:51:12Z","timestamp":1547751072000},"page":"e0210476","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7282-1225","authenticated-orcid":true,"given":"El\u017cbieta","family":"Jab\u0142onowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Siwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Boci\u0105ga-Jasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"G\u0105siorowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kalinowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Firl\u0105g Burkacka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamila","family":"W\u00f3jcik-Cichy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pi\u0105tek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Cielniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Horban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,1,17]]},"reference":[{"issue":"3","key":"ref1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/QAD.0000000000001335","article-title":"Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population","volume":"31","author":"A Gueler","year":"2017","journal-title":"AIDS"},{"key":"ref2","unstructured":"Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Updated: October 17 hangc."},{"key":"ref3"},{"issue":"8","key":"ref4","doi-asserted-by":"crossref","first-page":"656","DOI":"10.3109\/00365548.2011.572906","article-title":"Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naive patients","volume":"43","author":"L Calza","year":"2011","journal-title":"Scand J Infect Dis"},{"issue":"9","key":"ref5","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1097\/QAD.0000000000001067","article-title":"Bone mineral density decline according to renal tubular dysfunction and phosphaturia in tenofovir-exposed HIV-infected patients","volume":"30","author":"JL Casado","year":"2016","journal-title":"AIDS"},{"key":"ref6","article-title":"Adverse drug reactions to integrase strand transfer inhibitors","author":"KJ Lepik","year":"2018","journal-title":"AIDS"},{"issue":"2","key":"ref7","first-page":"229","article-title":"Adverse effects of antiretroviral therapy for HIV infection","volume":"170","author":"V Montessori","year":"2004","journal-title":"CMAJ"},{"issue":"6","key":"ref8","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1093\/jac\/dkx053","article-title":"Tolerability of integrase inhibitors in a real-life setting","volume":"72","author":"J Penafiel","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"ref9","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1097\/INF.0000000000000848","article-title":"Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents: Forty-eight-week Results from IMPAACT P1093","volume":"34","author":"RM Viani","year":"2015","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s13181-013-0325-8","article-title":"A review of the toxicity of HIV medications","volume":"10","author":"AM Margolis","year":"2014","journal-title":"J Med Toxicol"},{"issue":"5","key":"ref11","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/labinvest.2009.14","article-title":"Tenofovir renal toxicity targets mitochondria of renal proximal tubules","volume":"89","author":"JJ Kohler","year":"2009","journal-title":"Lab Invest"},{"issue":"7","key":"ref12","first-page":"580","article-title":"Renal tubular dysfunction associated with tenofovir therapy","volume":"62","author":"S Mitra","year":"2014","journal-title":"J Assoc Physicians India"},{"issue":"3","key":"ref13","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1345\/aph.1K522","article-title":"Abacavir hypersensitivity reaction: an update","volume":"42","author":"CA Hughes","year":"2008","journal-title":"Ann Pharmacother"},{"issue":"9622","key":"ref14","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(08)60423-7","article-title":"Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration","volume":"371","author":"DADS Group","year":"2008","journal-title":"Lancet"},{"issue":"14","key":"ref15","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/archinternmed.2010.197","article-title":"Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4","volume":"170","author":"S Lang","year":"2010","journal-title":"Arch Intern Med"},{"issue":"6","key":"ref16","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1177\/135965350300800605","article-title":"Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance","volume":"8","author":"JE Gallant","year":"2003","journal-title":"Antivir Ther"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1373\/clinchem.2006.077180","article-title":"Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values","volume":"53","author":"AS Levey","year":"2007","journal-title":"Clin Chem"},{"issue":"6","key":"ref18","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/jac\/dks057","article-title":"Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen","volume":"67","author":"J Burgos","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1186\/s12879-017-2755-4","article-title":"A dual regimen of ritonavir\/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational data","volume":"17","author":"AF Capetti","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"12","key":"ref20","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/jmv.24826","article-title":"Efficacy and safety of nucleoside-sparing regimen based on raltegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients","volume":"89","author":"E Jablonowska","year":"2017","journal-title":"J Med Virol"},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1310\/hct1303-119","article-title":"A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naive HIV-infected patients: SPARTAN study results","volume":"13","author":"MJ Kozal","year":"2012","journal-title":"HIV Clin Trials"},{"issue":"2","key":"ref22","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1089\/aid.2011.0275","article-title":"Lopinavir\/ritonavir combined with raltegravir or tenofovir\/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study","volume":"29","author":"J Reynes","year":"2013","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"3","key":"ref23","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s15010-015-0764-z","article-title":"Darunavir-based dual therapy of treatment-experienced HIV-infected patients: analysis from a national multicenter database","volume":"43","author":"G Sterrantino","year":"2015","journal-title":"Infection"},{"issue":"17","key":"ref24","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1097\/QAD.0b013e32834bbaa9","article-title":"Efficacy of a nucleoside-sparing regimen of darunavir\/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)","volume":"25","author":"B Taiwo","year":"2011","journal-title":"AIDS"},{"issue":"11","key":"ref25","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","article-title":"Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial","volume":"13","author":"F Raffi","year":"2013","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"ref26","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2147\/TCRM.S1709","article-title":"Combating HIV resistance\u2014focus on darunavir","volume":"4","author":"CL Tremblay","year":"2008","journal-title":"Ther Clin Risk Manag"},{"issue":"11","key":"ref27","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s40262-013-0093-2","article-title":"Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir","volume":"52","author":"ML Cottrell","year":"2013","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/hiv.12468","article-title":"Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients","volume":"18","author":"C Hoffmann","year":"2017","journal-title":"HIV Med"},{"issue":"3","key":"ref29","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/cid\/civ296","article-title":"The lipid-lowering effect of tenofovir\/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial","volume":"61","author":"JR Santos","year":"2015","journal-title":"Clin Infect Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0210476","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T15:23:06Z","timestamp":1662823386000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0210476"}},"subtitle":[],"editor":[{"given":"Cristian","family":"Apetrei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,1,17]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0210476","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,17]]}}}